Alphabiome AI
AI-Powered Microbiome Intelligence for Human Health
Company Overview
Snapshot
Founded in March 2022 by Yaniv Altshuler, Alphabiome AI operates with 1–10 employees. The company has raised $8M across four funding rounds, with AIX Ventures leading a Seed round in May 2025.
Business overview
Alphabiome AI leverages artificial intelligence to analyze the genetic complexities of the human microbiome. The company's core technology decodes microbial DNA to identify biomarkers, which are crucial for predicting treatment efficacy. This enables large-scale, reference-free analysis of genetic fragments, converting them into actionable insights for drug development, clinical decision-making, and precision medicine. Alphabiome AI operates within the Health Tech & Life Sciences sector, serving industries focused on healthcare, biotechnology, and personalized medicine.
Strategic signal
In May 2025, Alphabiome AI secured $8M in Seed funding, led by. This significant capital injection validates the company's AI-powered approach to microbiome intelligence and its potential to transform disease understanding and treatment. For investors, this signals strong market confidence in Alphabiome AI's proprietary technology and its strategic positioning within the rapidly evolving health tech and life sciences landscape.
Company Intelligence Q&A
- What is Alphabiome AI's primary focus?
- Alphabiome AI focuses on using artificial intelligence to decode the genetic complexity of the human microbiome, identifying biomarkers to predict treatment efficacy and transform disease understanding, diagnosis, and treatment.
- When was Alphabiome AI founded and by whom?
- Alphabiome AI was founded in March 2022 by Yaniv Altshuler.
- What was a significant funding event for Alphabiome AI?
- In May 2025, Alphabiome AI raised $8M in Seed funding, with.
- Which investor participated in Alphabiome AI's July 2024 funding round?
- In July 2024, iSelect Fund participated in a Seed funding round for Alphabiome AI.
- Which investor has made multiple investments in Alphabiome AI?
- New Era Capital Partners has made multiple investments in Alphabiome AI, including a Convertible Debt round in June 2022 and a SAFE round in April 2024.